Hsieh C.-H.Chang H.-T.Lin S.-C.Chen Y.-J.LI-YING WANGHsieh Y.-P.Chen C.-A.Chong N.-S.Lin S.L.Chen C.-Y.Shueng P.-W.2020-06-292020-06-2920101471-2407https://www.scopus.com/inward/record.uri?eid=2-s2.0-78650659959&doi=10.1186%2f1471-2407-10-696&partnerID=40&md5=83a9d1746a3fdd082dce16f32cf3666chttps://scholars.lib.ntu.edu.tw/handle/123456789/506314Background: Stereotactic body radiation therapy (SBRT) applied by helical tomotherapy (HT) is feasible for lung cancer in clinical. Using SBRT concurrently with erlotinib for non-small cell lung cancer (NSCLC) is not reported previously.Case Presentation: A 77-year-old man with stage III NSCLC, received erlotinib 150 mg/day, combined with image-guided SBRT via HT. A total tumor dose of 54 Gy/9 fractions was delivered to the tumor bed. The tumor responded dramatically and the combined regimen was well tolerated. After concurrent erlotinib-SBRT, erlotinib was continued as maintenance therapy. The patient developed dyspnea three months after the combined therapy and radiation pneumonitis with interstitial lung disease was suspected.Conclusions: Combination SBRT, HT, and erlotinib therapy provided effective anti-tumor results. Nonetheless, the potential risks of enhanced adverse effects between radiation and erlotinib should be monitored closely, especially when SBRT is part of the regimen. ? 2010 Hsieh et al; licensee BioMed Central Ltd.[SDGs]SDG3carcinoembryonic antigen; erlotinib; antineoplastic agent; EGFR protein, human; epidermal growth factor receptor; erlotinib; protein kinase inhibitor; quinazoline derivative; aged; article; case report; computer assisted tomography; dyspnea; human; interstitial lung disease; lung non small cell cancer; lung volume; maintenance therapy; male; multimodality cancer therapy; radiation pneumonia; stereotactic body radiation therapy; therapy effect; tomotherapy; tumor volume; adjuvant chemotherapy; adjuvant therapy; cancer staging; computer assisted radiotherapy; drug antagonism; dyspnea; enzymology; fatality; interstitial lung disease; lung non small cell cancer; lung tumor; radiation dose fractionation; radiation pneumonia; radiography; radiosurgery; time; treatment outcome; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Dose Fractionation; Dyspnea; Fatal Outcome; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Radiation Pneumonitis; Radiosurgery; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Receptor, Epidermal Growth Factor; Time Factors; Tomography, X-Ray Computed; Treatment Outcomejournal article10.1186/1471-2407-10-696211944442-s2.0-78650659959